ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2597

The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation

Jia (Sijia) Chen1, Roopa Madhu2, Catherine Manning3, Daniel Montoro4, Nataliya Yeremenko5, Kevin Wei6, ilya Korsunsky1, Dominique Baeten5 and Ellen Gravallese7, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Brookline, MA, 3Brigham and Women's Hospital, Dedham, MA, 4TenSixty Biosciences, Boston, MA, 5Amsterdam University Medical Centers, Amsterdam, Netherlands, 6Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

Meeting: ACR Convergence 2024

Keywords: Animal Model, autoimmune diseases, cytokines, Interleukins, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Abstracts: Cytokines & Cell Trafficking

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in homeostasis and inflammation. IL-17D is an understudied member of the IL-17 family of cytokines, and its function appears to be context-dependent. We sought to identify the role of IL-17D in inflammatory arthritis.

Methods: We induced serum transfer arthritis (STA) in IL-17D–deficient mice and controls and assessed clinical inflammation and cytokine expression by Luminex. We tested the effect of IL-17D in the development of inflammatory arthritis in both the STA and SKG models of arthritis. We assessed clinical inflammation and expression of pro-inflammatory factors in the paws by qPCR. We used the recently published single-cell RNA-seq atlas of inflamed synovium in rheumatoid arthritis (RA) patients (1) to identify the cell states expressing IL-17D. We used high-dimension transcriptomics data obtained by spatially profiling inflamed RA synovial tissues using CosMx and Xenium to map these IL-17D-expressing cells in situ. We performed colocalization analysis to identify statistically significant cell-cell interactions. We performed RNAscope and immunofluorescence (IF) to validate the results.

Results: IL-17D-deficient mice develop more severe arthritis than littermate controls. We show that treatment of arthritic mice with recombinant IL-17D protein attenuates inflammation in both the STA and SKG murine models of inflammatory arthritis, accompanied by downregulation of pro-inflammatory cytokines. IL-17D’s expression in human synovial tissue inversely correlates with local and systemic inflammation in RA patients. In RA synovial tissue, IL-17D mRNA is the most highly expressed in CD34+ stromal cells, which also express markers of stromal cell progenitors. Spatial transcriptomics profiling of inflamed RA synovium reveals that IL-17D+CD34+ stromal cells significantly colocalize with MERTK+SELENOP+LYVE1+ monocytes. Single-cell analysis and IF reveal the presence of one previously identified receptor for IL-17D, CD93, in inflamed synovial tissues.

Conclusion: IL-17D attenuates inflammation in two animal models of arthritis, and this finding is confirmed in the IL-17D-deficient setting. IL-17D and one receptor for IL-17D, CD93, are expressed in the inflamed RA synovial tissue. Although IL-17A and F are produced mainly by lymphocytes, IL-17D expression localizes to CD34+ stromal cells. The co-localization of IL-17D+CD34+ stromal cells with anti-inflammatory MERTK+SELENOP+LYVE1+ monocytes supports a potential interaction between these cell types to regulate inflammation. These data support a unique function of IL-17D among IL-17 family members by demonstrating an anti-inflammatory role for IL-17D in inflammatory arthritis.

References: 1) Zhang, F., Jonsson, A.H., Nathan, A. et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature 623, 616–624 (2023).


Disclosures: J. Chen: None; R. Madhu: None; C. Manning: None; D. Montoro: None; N. Yeremenko: None; K. Wei: 10X Genomics, 5, Gilead sciences, 2, Merck/MSD, 5, Mestag, 2, santa ana bio, 2; i. Korsunsky: Mestag Therapeutics LTD, 2; D. Baeten: Interlaken Therapeutics, 3, UCB, 3, Weatherden, 3; E. Gravallese: Beam Therapeutics, 11, CRISPR Therapeutics, 11, Editas Medicine, 11, Intellia Therapeutics, 11, New England Journal of Medicine, 3, NIH, 5, Rheumatology Research Foundation, 5.

To cite this abstract in AMA style:

Chen J, Madhu R, Manning C, Montoro D, Yeremenko N, Wei K, Korsunsky i, Baeten D, Gravallese E. The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-stromal-cell-derived-cytokine-interleukin-17d-attenuates-joint-inflammation-2/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-stromal-cell-derived-cytokine-interleukin-17d-attenuates-joint-inflammation-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology